Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

被引：0
|
作者：
Stefania Bulotta
Marilena Celano
Giuseppe Costante
Diego Russo
机构：
[1] University “Magna Graecia” of Catanzaro,Department of Health Sciences
[2] Institut Jules Bordet Comprehensive Cancer Center,Endocrinology Clinic, Internal Medicine Department
来源：
Endocrine | 2016年 / 52卷
关键词：
Differentiated thyroid cancer; Radioiodine; Molecular targets; Re-differentiation strategies; Nanodevices;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.
引用
收藏
页码：214 / 221
页数：7
相关论文
共 50 条
  • [21] Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications
    Van Nostrand, Douglas
    THYROID, 2018, 28 (09) : 1083 - 1093
  • [22] Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
    Ovcaricek, Petra Petranovic
    Campenni, Alfredo
    de Keizer, Bart
    Deandreis, Desiree
    Kreissl, Michael C.
    Vrachimis, Alexis
    Tuncel, Murat
    Giovanella, Luca
    CANCERS, 2023, 15 (17)
  • [23] Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
    Du, Wei
    Shi, Xiangyu
    Fang, Qigen
    Zhang, Xu
    Liu, Shanting
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [24] Clinical and molecular profiles of radioiodine refractory differentiated thyroid cancer
    Lin, Y.
    Zhang, X.
    He, H.
    Huang, L.
    Ding, S.
    Kai, Z.
    Lin, R.
    Luo, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1300 - S1300
  • [25] Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas
    Wassermann, Johanna
    Bernier, Marie-Odile
    Spano, Jean-Philippe
    Lepoutre-Lussey, Charlotte
    Buffet, Camille
    Simon, Jean-Marc
    Menegaux, Fabrice
    Tissier, Frederique
    Leban, Monique
    Leenhardt, Laurence
    ONCOLOGIST, 2016, 21 (01): : 50 - 58
  • [26] Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers
    Paeng J.C.
    Kang K.W.
    Park D.J.
    Oh S.W.
    Chung J.-K.
    Nuclear Medicine and Molecular Imaging, 2011, 45 (4) : 241 - 247
  • [27] Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets
    Spitzweg, Christine
    Bible, Keith C.
    Hofbauer, Lorenz C.
    Morris, John C.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (10): : 830 - 842
  • [28] Radioiodine treatment and oxidative stress in thyroidectomised patients for differentiated thyroid cancers
    Konukoglu, D
    Hatemi, HH
    Arikan, S
    Demir, M
    Akcay, T
    PHARMACOLOGICAL RESEARCH, 1998, 38 (04) : 311 - 315
  • [29] Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
    Herranz, Urbano Anido
    CANCER MEDICINE, 2022, 11 : 47 - 53
  • [30] Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
    Tumino, Dario
    Frasca, Francesco
    Newbold, Kate
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
12345